- Home
- GUTS vs CUE Comparison
GUTS vs CUE Comparison
Compare GUTS & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- CUE
- Stock Information
- Founded
- GUTS 2010
- CUE 2014
- Country
- GUTS United States
- CUE United States
- Employees
- GUTS N/A
- CUE N/A
- Industry
- GUTS
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- GUTS
- CUE Health Care
- Exchange
- GUTS NYSE
- CUE Nasdaq
- Market Cap
- GUTS 54.8M
- CUE 60.6M
- IPO Year
- GUTS 2024
- CUE 2018
- Fundamental
- Price
- GUTS $1.33
- CUE $0.84
- Analyst Decision
- GUTS Buy
- CUE Strong Buy
- Analyst Count
- GUTS 1
- CUE 3
- Target Price
- GUTS $10.00
- CUE $3.00
- AVG Volume (30 Days)
- GUTS 292.5K
- CUE 220.7K
- Earning Date
- GUTS 05-12-2025
- CUE 05-08-2025
- Dividend Yield
- GUTS N/A
- CUE N/A
- EPS Growth
- GUTS N/A
- CUE N/A
- EPS
- GUTS N/A
- CUE N/A
- Revenue
- GUTS $93,000.00
- CUE $9,287,000.00
- Revenue This Year
- GUTS N/A
- CUE N/A
- Revenue Next Year
- GUTS N/A
- CUE $4.77
- P/E Ratio
- GUTS N/A
- CUE N/A
- Revenue Growth
- GUTS N/A
- CUE 69.16
- 52 Week Low
- GUTS $0.87
- CUE $0.45
- 52 Week High
- GUTS $7.89
- CUE $2.26
- Technical
- Relative Strength Index (RSI)
- GUTS 56.78
- CUE 48.41
- Support Level
- GUTS $0.87
- CUE $0.74
- Resistance Level
- GUTS $1.39
- CUE $0.80
- Average True Range (ATR)
- GUTS 0.12
- CUE 0.09
- MACD
- GUTS 0.05
- CUE 0.02
- Stochastic Oscillator
- GUTS 88.39
- CUE 83.49
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.